Skip to main content
padlock icon - secure page this page is secure

Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature

Buy Article:

$68.00 + tax (Refund Policy)

This review addresses recent developments in amyloid β (Aβ), total tau (t-tau) and phosporylated tau (p-tau) protein analysis, in cerebrospinal fluid (CSF) and plasma as biomarkers for dementia. Recent research focused on the progression of patients with mild cognitive impairment (MCI) into dementia and the differential diagnosis of Alzheimer's Disease (AD).

A combination of Aβ42 and t-tau in CSF can discriminate between patients with stable MCI and patients with progressive MCI into AD or other types of dementia with a sufficient sensitivity and specificity. Regression analyses demonstrated that pathological CSF (with decreased Aβ42 and increased tau levels) is a very strong predictor for the progression of MCI into AD.

Furthermore, CSF measurements of p-tau and Aβ42 can assist in diagnosing vascular dementia or frontotemporal dementia in the differential diagnosis of AD indicated by a reasonable sensitivity and specificity. Whether tau in combination with Aβ42 or in combination with the Aβ37/Aβ42 or Aβ38/Aβ42 ratio aids in the discrimination between AD and Lewy Body dementia remains to be elucidated.

Cross-sectional research could not demonstrate significant differences for Aβ40 and Aβ42 in plasma between AD and controls. However, a recently published longitudinal study showed high baseline Aβ40 levels, especially when combined with low baseline Aβ42 levels, is a strong risk factor for the development of dementia. This emphasises the importance of performing longitudinal studies in addition to cross-sectional ones. The origin of plasma Aβ and its transport between CSF and plasma, however, needs further clarification.

In conclusion, progress has been made regarding Aβ and tau as biomarkers for dementia both for differentiation between stable MCI and progressive MCI patients and for the differential diagnosis of AD. Future research should aim to validate these recently published results, preferably in pathologically confirmed AD patients. In addition, it is important to standardise research in terms of study design (longitudinal, minimal follow-up period of 5 years), type of researched parameters (total or p-tau, type of Aβ peptides), type of matrix (CSF and plasma) and data analysis (establishment of predefined cut-off values, type of ratio, type of marker combination).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer disease; Amyloid precursor protein; CSF biomarkers; Lewy Body Dementia; mild cognitive impairment (MCI)

Document Type: Research Article

Publication date: May 1, 2008

More about this publication?
  • Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more